https://www.selleckchem.com/pr....oducts/sanguinarine-
During PREVENT (NCT01892345), eculizumab significantly reduced relapse risk versus placebo in patients with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD). We report an interim analysis of PREVENT's ongoing open-label extension (OLE; NCT02003144) evaluating eculizumab's long-term safety and efficacy. Patients who completed PREVENT could enroll in the OLE to receive eculizumab (maintenance dose=1,200 mg/2 weeks, after a blinded induction phase). Safety and efficacy data from P
Like
Comment
Share
